Benitec Biopharma Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Benitec Biopharma kazanç ve gelirinin sırasıyla yıllık 2.2% ve 65.2% oranında artması tahmin edilirken, EPS'nin yıllık 7.3% oranında büyümesi bekleniyor.

Anahtar bilgiler

2.2%

Kazanç büyüme oranı

7.32%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.8%
Gelir büyüme oranı	65.2%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	19 Aug 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Analiz Makalesi • Aug 07

Here's Why We're Not At All Concerned With Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Seeking Alpha • Jan 31

Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade

Summary Benitec Biopharma is basically a single-asset genetic medicine story. Their lead asset is BB-301 for OPMD dysphagia. Their mechanism of action works through an AAV "silence-and-replace" approach (silence the mutant gene and replace it with a functional copy). BNTC’s Phase 1b/2a Cohort 1 shows a 100% responder rate with favorable safety. They reported durability anecdotes that also strengthen the setup at this point. Thus, I feel BNTC is well positioned for their mid-2026 FDA pivotal-design meeting. However, they have no product revenues yet, which makes it speculative. Overall, I think their strengthened balance sheet and clear regulatory catalysts now justify a bullish stance, which is why I upgrade the stock to a speculative “Buy.”. Read the full article on Seeking Alpha

Analiz Makalesi • Oct 16

Companies Like Benitec Biopharma (NASDAQ:BNTC) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Benitec Biopharma...

Analiz Makalesi • Nov 30

Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable

Key Insights Benitec Biopharma will host its Annual General Meeting on 6th of December CEO Jerel Banks' total...

Seeking Alpha • Sep 13

Benitec Biopharma prices of $18M securities offering

Benitec Biopharma (NASDAQ:BNTC) has priced its underwritten public offering of 29,809,471 shares of its common stock and accompanying warrants to purchase up to 29,809,471 shares of common stock for an expected gross proceeds to be approximately $17.9M. Each share of common stock is being sold together with one common warrant to purchase one share of common stock at a combined offering price of $0.60. The warrants will be exercisable commencing on the effective date of an increase in our authorized shares of common stock at an exercise price of $0.66/share of common stock and will expire on the fifth anniversary of such initial exercise date. Offering is expected to close on September 15, 2022. Net proceeds from this financing will be used for the clinical development of BB-301, for the continued advancement of development activities for other existing and new product candidates, for general corporate purposes and for strategic growth opportunities.

Seeking Alpha • Sep 02

Benitec GAAP EPS of -$2.23, revenue of $0.07M

Benitec press release (NASDAQ:BNTC): FY GAAP EPS of -$2.23. Revenue of $0.07M (+16.7% Y/Y).

Analiz Makalesi • Jan 13

We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Analiz Makalesi • Sep 30

We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • May 12

Will Benitec Biopharma (NASDAQ:BNTC) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Analiz Makalesi • Jan 27

Can Benitec Biopharma (NASDAQ:BNTC) Afford To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analiz Makalesi • Dec 02

How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?

Jerel Banks has been the CEO of Benitec Biopharma Inc. ( NASDAQ:BNTC ) since 2018, and this article will examine the...

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:BNTC - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2029	N/A	-98	-28	-88	3
6/30/2028	N/A	-81	-39	-67	3
6/30/2027	18	-60	-11	-39	6
6/30/2026	N/A	-46	-36	-27	6
3/31/2026	N/A	-42	-20	-20	N/A
12/31/2025	N/A	-44	-18	-18	N/A
9/30/2025	N/A	-42	-22	-22	N/A
6/30/2025	N/A	-38	-24	-24	N/A
3/31/2025	N/A	-34	-19	-19	N/A
12/31/2024	N/A	-24	-22	-22	N/A
9/30/2024	N/A	-21	-20	-19	N/A
6/30/2024	N/A	-22	-20	-19	N/A
3/31/2024	0	-22	-20	-20	N/A
12/31/2023	0	-22	-18	-18	N/A
9/30/2023	0	-21	-19	-19	N/A
6/30/2023	0	-20	-18	-18	N/A
3/31/2023	0	-20	-19	-19	N/A
12/31/2022	0	-19	-18	-18	N/A
9/30/2022	0	-18	-16	-16	N/A
6/30/2022	0	-18	-16	-16	N/A
3/31/2022	0	-17	-16	-16	N/A
12/31/2021	0	-18	-15	-15	N/A
9/30/2021	0	-16	-15	-15	N/A
6/30/2021	0	-14	-13	-13	N/A
3/31/2021	0	-13	-11	-11	N/A
12/31/2020	0	-11	-10	-10	N/A
9/30/2020	0	-10	-10	-9	N/A
6/30/2020	0	-8	-8	-8	N/A
3/31/2020	1	-7	-6	-6	N/A
12/31/2019	1	-6	N/A	N/A	N/A
9/30/2019	7	-2	N/A	2	N/A
6/30/2019	12	3	N/A	5	N/A
3/31/2019	12	2	N/A	4	N/A
12/31/2018	12	2	N/A	N/A	N/A
9/30/2018	8	-3	N/A	-3	N/A
6/30/2018	3	-9	N/A	-7	N/A
3/31/2018	4	-9	N/A	-7	N/A
12/31/2017	6	-7	N/A	-5	N/A
9/30/2017	5	-7	N/A	-5	N/A
6/30/2017	9	-4	N/A	-6	N/A
3/31/2017	7	-7	N/A	-6	N/A
12/31/2016	7	-8	N/A	-10	N/A
9/30/2016	7	-12	N/A	-13	N/A
6/30/2016	3	-18	N/A	-15	N/A
3/31/2016	3	-18	N/A	-17	N/A
12/31/2015	2	-16	N/A	-14	N/A
9/30/2015	2	-12	N/A	-10	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: BNTC önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: BNTC önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: BNTC önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: BNTC şirketinin gelirinin (yıllık 65.2% ) US pazarından (yıllık 13.5% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: BNTC şirketinin gelirinin (yıllık 65.2% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: BNTC 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/09/10 18:17
Gün Sonu Hisse Fiyatı	2026/09/10 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/06/30

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Benitec Biopharma Inc. 9 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Brian Skorney	Baird
Silvan Tuerkcan	Citizens JMP Securities, LLC
Cory Kasimov	Evercore ISI

Benitec Biopharma Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 8.3% to US$25.80

Price target increased by 9.3% to US$27.17

Price target increased by 7.1% to US$25.71

Recent updates

Here's Why We're Not At All Concerned With Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Situation

Price target increased by 8.3% to US$25.80

Benitec Biopharma Inc. Announces Board Changes, Effective May 22, 2026

New major risk - Revenue and earnings growth

New minor risk - Profitability

Benitec Biopharma Inc. Announces Positive Interim Phase 1b/2a Results For High Dose BB-301 And Continued Durable Improvements For Low Dose BB-301 Treatment

Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade

New minor risk - Share price stability

Benitec Biopharma Inc. Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response

Price target increased by 9.3% to US$27.17

New major risk - Shareholder dilution

Benitec Biopharma Inc. has completed a Follow-on Equity Offering in the amount of $80.055 million.

Benitec Biopharma Inc. has filed a Follow-on Equity Offering.

Less than half of directors are independent

Benitec Biopharma Inc. Appoints Sharon Mates to the Board of Directors, Effective November 2, 2025

Companies Like Benitec Biopharma (NASDAQ:BNTC) Can Afford To Invest In Growth

Benitec Biopharma Inc., Annual General Meeting, Dec 01, 2025

Benitec Biopharma Inc. Provides Operational Updates

Benitec Biopharma Inc.(NasdaqCM:BNTC) dropped from Russell 3000E Value Index

Companies Like Benitec Biopharma (NASDAQ:BNTC) Can Afford To Invest In Growth

Price target increased by 7.1% to US$25.71

Benitec Biopharma Inc. has completed a Follow-on Equity Offering.

Benitec Biopharma Inc. has filed a Follow-on Equity Offering.

Benitec Biopharma Inc. has filed a Follow-on Equity Offering in the amount of $37.50357 million.

Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to Be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Independent Non-Executive Director exercised options to buy US$620k worth of stock.

New minor risk - Share price stability

Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference

Benitec Biopharma: Early Positive Data, Small Target Market, Little Competition

Benitec Biopharma Inc., Annual General Meeting, Dec 04, 2024

New major risk - Revenue and earnings growth

Benitec Biopharma Inc. Reports Positive Data from Two Subjects Treated with Low-Dose Bb-301 in Phase 1B/2A Study Presented At 29Th Annual Congress of the World Muscle Society

Benitec Biopharma Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Companies Like Benitec Biopharma (NASDAQ:BNTC) Are In A Position To Invest In Growth

Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-Dose BB-301 in Phase 1b/2a Study

Benitec Biopharma Inc. Announces Appointment of Kishen Mehta to Its Board of Directors

Third quarter 2024 earnings released: US$1.64 loss per share (vs US$2.67 loss in 3Q 2023)

Benitec Biopharma Inc. announced that it has received $40.000019 million in funding from a group of investors

New major risk - Share price stability

Benitec Biopharma Inc. Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study

New minor risk - Share price stability

Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable

Benitec Biopharma Announces First Subject Dosed in Phase 1B/2A Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

New major risk - Financial position

Benitec Biopharma Inc., Annual General Meeting, Dec 06, 2023

Full year 2023 earnings released: US$14.12 loss per share (vs US$37.88 loss in FY 2022)

Benitec Biopharma Regains Compliance with the Bid Price Rule

Benitec Biopharma Provides Nasdaq Compliance Update

New major risk - Share price stability

Insufficient new directors

Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program

Benitec Biopharma prices of $18M securities offering

Full year 2022 earnings: EPS and revenues miss analyst expectations

Benitec GAAP EPS of -$2.23, revenue of $0.07M

Third quarter 2022 earnings released: US$0.40 loss per share (vs US$0.82 loss in 3Q 2021)

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate

First quarter 2022 earnings released: US$0.62 loss per share (vs US$2.45 loss in 1Q 2021)

We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully

Full year 2021 earnings released: US$3.23 loss per share (vs US$8.10 loss in FY 2020)

Third quarter 2021 earnings released: US$0.82 loss per share (vs US$1.96 loss in 3Q 2020)

Will Benitec Biopharma (NASDAQ:BNTC) Spend Its Cash Wisely?

New 90-day low: US$2.59

New 90-day high: US$4.71

Can Benitec Biopharma (NASDAQ:BNTC) Afford To Invest In Growth?

New 90-day high: US$3.88

New 90-day high: US$3.34

How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?

First quarter 2021 earnings released: US$2.45 loss per share

New 90-day low: US$2.76

New 90-day low: US$4.79

Full year earnings released - US$8.10 loss per share